BCR and central nervous system cancer: Patient CL0238, previously reported by our group to harbor a pathogenic fusion gene BCR-ABL [14], was diagnosed with a NHMP glioma that also had a high percentage of shared mutations, indicating that the fusion event of BCR-ABL occurred early and that it is an oncogenic driver leading to rapid progression of disease without significant clonal divergence.